Approval for OTC use of a urine drug test that can be performed by non-CLIA facilities could help expand accessibility, expert says.
Rachel Rangel, AuD, discusses a new toolkit to help laboratory professionals ensure diversity and inclusion is addressed in their research.
Lab leaders say that the increased level of scrutiny proposed for such tests would be a detriment to innovation and patient care.
Genomic sequencing is almost twice as likely to yield a diagnostic result, but lags behind panel testing in speed, cost, and concordance.
Tackling the challenges of “forever chemicals” in the diagnostics industry.